linjc16/ctgov huggingface dataset:
Detection of Celiac Disease in Patients With Hypothyroidism

Study Overview
=================
Brief Summary
-----------------
The study evaluates whether hypothyroid patients requiring elevated doses of levothyroxine to maintain a euthyroid state are at increased risk of having celiac disease. It also attempts to determine if there is a threshold level of levothyroxine needed to maintain a euthyroid state in patients with hypothyroidism that should prompt serologic testing for celiac disease.

Detailed Description
-----------------
This study is looking at whether hypothyroid patients who require above 125 mcg/day (or >1.5mcg/kg/day) of levothyroxine are more likely to have celiac disease than those who require smaller doses. It also looks to see if the prevalence of celiac disease in hypothyroid patients who require elevated doses of levothyroxine is high enough to warrant screening in that population.

Official Title
-----------------
Detection of Celiac Disease in Patients With Hypothyroidism

Conditions
-----------------
Celiac Disease, Hypothyroidism, Celiac Sprue, Malabsorption

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with the diagnosis of hypothyroidism that require thyroid replacement therapy. Exclusion Criteria: Surgical resection of thyroid tissue, neck irradiation, radioactive iodine therapy, prior medical treatment with lithium, methimazole, propylthiouracil, ethionamide, amiodarone, or sunitinib, prior serologic testing for celiac disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| presence of celiac disease |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms associated with celiac disease | a short questionnaire will be filled out at the time of serologic testing. If a patient hads celiac disease the form will be filled out again at 6 months after diagnosis. | 6 months | 
| medication adjustment | Patients diagnosed with celiac disease who initiate a gluten free diet will be assessed to determine whether adjustment of levothyroxine dosing is necessary | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Celiac Disease, Hypothyroidism, Celiac Sprue, Malabsorption
Aortic Wall and Left Ventricular Mechanics: Echocardiographic and Hemodynamic Analysis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to prospectively determine the relationship between the dimensions of the aorta (the large artery taking off the heart) and blood pressure during cardiac surgery.

Detailed Description
-----------------
The purpose of this study is to prospectively determine the relationship between the dimensions of the aorta (the large artery taking off the heart) and blood pressure during cardiac surgery. Measurements of the aorta are obtained by an ultrasound-based imaging technique called transesophageal echocardiography (TEE), which is routinely performed during cardiac surgery. TEE is an instrument used to monitor the heart and is standard of practice at Weill Cornell Medical College.

Official Title
-----------------
Aortic Wall and Left Ventricular Mechanics: Echocardiographic and Hemodynamic Analysis

Conditions
-----------------
Coronary Disease, Cardiac Valve Disease

Intervention / Treatment
-----------------
* Procedure: TEE report


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective CABG, valvular procedure Exclusion Criteria: non-sinus rhythm (atrial fibrillation, flutter, paced rhythm), pre-operative presence of intra-aortic counterpulsation device, synthetic aortic graft.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TEE report<br>Cardiac surgery patients requiring TEE | Procedure: TEE report<br>* Information will be collected during cardiac surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure the dimensions of the aorta and compare with blood pressure measurements |  | 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TEE, Cardiac Surgery, Pulse Pressure
Effect of Remote Ischemic Preconditioning on Cognitive Function After Off-Pump Coronary Artery Bypass Graft

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the effects of remote ischemic preconditioning on cognitive function in patients undergoing off-pump coronary artery bypass graft.

Official Title
-----------------
Effect of Remote Ischemic Preconditioning on Cognitive Function After Off-Pump Coronary Artery Bypass Graft

Conditions
-----------------
Ischemic Heart Disease

Intervention / Treatment
-----------------
* Procedure: remote ischemic preconditioning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing elective off-pump coronary artery bypass graft surgery Exclusion Criteria: Emergency operation Preoperative use of inotropic drugs or mechanical assistant device Ejection fraction less than 30% Combined operation using CPB such as valve surgery Previous psychiatric and neurologic disorder Inability to perform the cognitive function test

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Remote ischemic preconditioning<br>Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis | Procedure: remote ischemic preconditioning<br>* Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis<br>|
| Placebo Comparator: control<br>sham placement of a blood-pressure cuff around the upper limb without inflation | Procedure: remote ischemic preconditioning<br>* Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cognitive function |  | preoperative, 1 week and 6 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
remote ischemic preconditioning, cognitive function, off-pump coronary artery bypass graft
Safety of Diclofenac Sodium Gel in Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
This study will test the efficacy and safety of topical Voltaren in the treatment of knee osteoarthritis.

Official Title
-----------------
Safety of Diclofenac Sodium Gel in Knee Osteoarthritis

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Diclofenac Topical Sodium Gel 1%


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion criteria • Osteoarthritis of the knee Key Exclusion criteria Other rheumatic disease, such as rheumatoid arthritis Active gastrointestinal ulcer during the last year Known allergy to analgesic drugs

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Diclofenac Topical Sodium Gel 1%|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of treatment-emergent adverse events |  |  | 
| Number of laboratory values outside pre-determined ranges at Months 1, 3, 6, 9 and 12 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of serious treatment-emergent adverse events |  |  | 
| Number of patients who discontinued study medication due to a treatment-emergent adverse event |  |  | 
| WOMAC pain, physical function and stiffness scores at Months 3, 6, 9 and 12 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Knee osteoarthritis, Topical NSAID, Diclofenac sodium
PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells

Study Overview
=================
Brief Summary
-----------------
The proliferation and distribution of CD19 CAR-T cells in lymphoma patients are investigated 68Ga-NOTA-RP25 by PET / CT imaging.

Detailed Description
-----------------
The purpose of this study is to monitor the proliferation and distribution of CD19 CAR-T cells in lymphoma patients by using a novel specific PET tracer 68Ga-NOTA-RP25 for monitoring the proliferation of CAR-T cells.

Official Title
-----------------
PET / CT Imaging and Safety of the 68Ga-NOTA-RP25 Molecular Probe in Patients With Lymphoma Who Have Received Prior Therapy Containing CD19 CAR-T Cells

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Diagnostic Test: 68Ga-NOTA-RP25


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. The subjects voluntarily signed the informed consent form and were able to complete the test according to the protocol requirements; 2. Over 18 years old, male or female; 3. Diagnosed as lymphoma and intended to receive CD19 car-t treatment; 4. ECOG score is 0-1; The estimated survival time shall not be less than 3 months; Exclusion Criteria: 1. Participate in other clinical trials other than CAR-T treatment at the same time or within 28 days. If participating in a non intervention clinical trial, it can be included in this study; 2. Patients with a history of allergy; 3. Patients who cannot tolerant PET / CT imaging； 4. Patients who are using anticoagulant drugs or need to use anticoagulant drugs during the study;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 68Ga-NOTA-RP25<br>Intravenous injection | Diagnostic Test: 68Ga-NOTA-RP25<br>* The proliferation and distribution of CD19 CAR-T cells in lymphoma patients were investigated by PET / CT after injection of 68Ga-NOTA-RP25<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SUV value of radioactive material uptake in the region of interest | According to the PET / CT imaging results of 68Ga-NOTA-RP25 after iterative reconstruction, PMOD software is used to outline the tumor, brain, liver, heart, tumor and other tissues as regions of interest (ROI) | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety evaluation index | To observe AE/SAE of subjects | 1 month |
Effect of Prednisone and Aspirin on IVF-ET Outcome Among Patients With Thyroid Autoimmunity

Study Overview
=================
Brief Summary
-----------------
This trial was a 1:1 (active:placebo) randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of prednisone and aspirin for the in vitro fertilization and embryo transfer outcome among patients with thyroid autoimmunity.

Official Title
-----------------
Effect of Prednisone and Aspirin on Pregnancy Outcomes After Embryo Transfer Among Patients With Thyroid Autoimmunity: a Randomized Clinical Trial

Conditions
-----------------
Infertility, Thyroiditis, Autoimmune

Intervention / Treatment
-----------------
* Drug: Prednisone and Aspirin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: TPOAb>34IU/ml and/or TgAb>115IU/ml ≥5 follicles with average diameter lager than 14 mm at trigger day ≥5 oocytes retrieved for frozen embryo transfer, at least 2 cleavage stage embryos, among which at least one morphologically good quality embryo, or at least 1 morphologically good quality embryo in blastocyst stage age: 20-38 years old Patients whose written ICF approved by the EC has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved. meet item 1, 5, 6, and one of item 2, 3, 4. Exclusion Criteria: hyperthyroidism intrauterine adhesion with endometrium thickness less than 6mm uterine malformation PGT with other autoimmune diseases need glucocorticoid or aspirin treatment gluacoma gastric ulcer

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: prednisone and aspirin<br> | Drug: Prednisone and Aspirin<br>* prednisone 10 mg and aspirin 75-100mg per day per os<br>|
| Placebo Comparator: placebo<br> | Drug: Placebo<br>* placebo 2 starch tablets per day per os<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical pregnancy rate | ultrasound visualization of the gestational sac | 3-5 weeks after embryo transfer |
Goal-directed Fluid Resuscitation in Acute Pancreatitis

Study Overview
=================
Brief Summary
-----------------
Vigorous fluid resuscitation is currently believed to play a key role in reducing complications associated with acute pancreatitis. However, aggressive fluid replacement can be associated with complications such as pulmonary fluid sequestration. The purpose of this study is to evaluate alternative approaches to early fluid resuscitation for patients with acute pancreatitis.

Detailed Description
-----------------
Primary Aim: Evaluate the impact of a goal-directed fluid resuscitation protocol compared to standard fluid resuscitation on systemic inflammation in patients with acute pancreatitis. Secondary Aim: Evaluate the impact of resuscitation with Lactated Ringer's compared to normal saline on systemic inflammation in acute pancreatitis.

Official Title
-----------------
A Randomized-controlled Trial of a Targeted Approach to Fluid Resuscitation in Acute Pancreatitis

Conditions
-----------------
Acute Pancreatitis

Intervention / Treatment
-----------------
* Other: Goal-directed fluid resuscitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute pancreatitis diagnosed by at least 2 criteria adult patients at least 18 years of age Exclusion Criteria: history of severe cardiovascular, respiratory, renal, hepatic or hematologic/immunologic disease concurrent metabolic or physiologic derangement requiring specific fluid management pregnancy patients transferred from acute care hospital

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Goal-directed fluid resuscitation with lactated Ringer's solution | Other: Goal-directed fluid resuscitation<br>* Targeted, weight-based fluid resuscitation<br>|
| Experimental: 2<br>Goal-directed fluid resuscitation with normal saline | Other: Goal-directed fluid resuscitation<br>* Targeted, weight-based fluid resuscitation<br>|
| No Intervention: 3<br>Standard fluid resuscitation with lactated Ringer's solution | |
| No Intervention: 4<br>Standard fluid resuscitation with normal saline | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence (point prevalence) of the systemic inflammatory response syndrome (SIRS) at 24 hours |  | first 24 hours of hospitalization |
Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy

Study Overview
=================
Brief Summary
-----------------
Hypotheses: Decompressive surgery of cervical myelopathy will improve bladder function. Decompressive surgery of cervical myelopathy will improve sexual function.

Detailed Description
-----------------
The investigators will enroll consecutive cohort with cervical myelopathy who are scheduled to take surgical decompression of cervical spinal cord, aged between 25 and 65. The exams for the patients include followings JOA (Japanese Orthopaedic Association) Scores for cervical myelopathy VAS (Visual Analog Scale) pain score IPSS (International Prostate Symptom Score) and IIEF (International Index of Erectile Function) in male patients FSFI (Female Sexual Function Index) and UDI (Urinary Distress Inventory) in female patients Bladder compliance, Detrusor leak point pressure, Peak detrusor pressure Rigidity activity unit of penis

Official Title
-----------------
Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy

Conditions
-----------------
Myelopathy, Neurogenic Bladder, Erectile Dysfunction, Psychosexual Dysfunctions, Sexual Arousal Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: evidence of progression of motor or sensory nerve cervical myelopathy in magnetic resonance imaging Exclusion Criteria: radical pelvic surgery pelvic irradiation evidence of brain damage (dementia, cerebrovascular disease) evidence of psychotic disorder

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Decompression of cervical myelopathy<br>JOA (Japanese Orthopaedic Association) Scores for cervical myelopathy Compliance Rigidity activity unit | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| JOA (Japanese Orthopaedic Association) Scores for cervical myelopathy | This score will provide patients' conditions at a glance. | 6 months after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bladder compliance | This will be provided by urodynamic study, and will show the intactness of Guarding reflex from upper spinal cord tract. | 6 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myelopathy
Effect of Nigella Sativa on Lipid Profiles in Elderly

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Nigella sativa seed extracts are effective in the treatment of dyslipidemia in elderly.

Detailed Description
-----------------
Cardiovascular diseases are still common health problems worldwide. They are major causes of morbidity and mortality in many countries. Dyslipidemia is the main risk factor of cardiovascular events. Despite the invention of many conventional hypolipidemic drugs, the use of traditional medicine remains high, especially in elderly patients. However, evidence of the effectiveness of many herbs or other traditional drugs is lacking. Nigella sativa or black seeds are traditional herbs used for years in Middle East and India. They are believed to cure many diseases, including dyslipidemia. Therefore, a study is needed to prove their effectiveness as their use might improve our strategy to improve patients' compliance.

Official Title
-----------------
Effect of Nigella Sativa on Lipid Profiles in Elderly: a Randomized Double-blinded Clinical Trial

Conditions
-----------------
Dyslipidemia

Intervention / Treatment
-----------------
* Drug: Nigella sative
* Dietary Supplement: black sticky rice


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age of 60 years or more having dyslipidemia (total cholesterol >200 mg/dL or LDL >100 mg/dL or triglyceride > 150 mg/dL or HDL < 40 mg/dL (male) or HDL < 50 mg/dL (female) Exclusion Criteria: ALT or AST are two times of upper normal limit creatinine clearance test is below 30

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nigella sativa<br>Nigella sativa extracts, 300 mg twice daily | Drug: Nigella sative<br>* Nigella sativa seed extracts, 300 mg capsule bid, for 56 days<br>|
| Placebo Comparator: Placebo<br> | Dietary Supplement: black sticky rice<br>* 300 mg capsule bid, 56 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decreased level of total cholesterol, LDL, dan triglyceride, and increased level of HDL |  | 56 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nigella sativa, dyslipidemia, elderly